AbbVie’s mega-blockbuster Humira is finally subject to biosimilar competition in the United States. With the launch last month of Amgen’s Amjevita—to be followed later this year by other Humira biosimilars entering the market—patients finally have access to lower-cost alternatives to the immunology blockbuster.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,